Adagio Medical reports Q1 2026 net loss $7.0M, cash $12.9M; FULCRUM-VT shows 84% freedom from ICD shock

Adagio Medical Holdings, Inc.

2026-Q1 EPS reported -$0.31

Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.
Cash and equivalents of $12.9M as of March 31, 2026; up to $31M additional from milestone-based warrants.
FULCRUM-VT pivotal trial: 84% freedom from ICD shock at 6 months, 2.4% MAE, 72% reduction in antiarrhythmic drug use.
FDA approved IDE to expand FULCRUM-VT trial to evaluate next-generation vCLAS Ultra System.
Successfully completed 13 cases under FDA Expanded Access in patients who failed prior ablation therapies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Adagio Medical Holdings, Inc. reported three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $7.0 million.

Period: three months ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $7.0 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026 was $7.0 million, compared to a net loss of $7.7 million for the three months ended March 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Adagio Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.